Valneva is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

2019年7月11日 · We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Our vision is to contribute to a world where no one dies …

Valneva USA Inc. is focused on the marketing and distribution of Valneva’s vaccine for Chikungunya and Japanese Encephalitis.

Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston , Scotland; Solna , Sweden, and Vienna , Austria; with other offices in …

2025年1月20日 · Saint-Herblain (France), January 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ®, which showed a sustained 98.3% sero-response rate one-year after single vaccination.

3 天之前 · Valneva announced last week that it has responded to the French government’s call for supply of IXCHIQ ® in La Réunion and that it will provide 40,000 doses to the Island’s wholesalers, with ...

Valneva is a specialty vaccine company that develops, manufactures, and commercializes vaccines for infectious diseases addressing unmet medical needs. Valneva USA, Inc. is focused on the marketing and distribution of Valneva’s Chikungunya vaccine and Valneva’s Japanese Encephalitis vaccine.

2022年12月，法国卫生当局建议不要使用当地疫苗公司valneva(valn.us)的新冠肺炎疫苗，而建议使用赛诺菲(sny.us)和葛兰素史克(gsk.us)以及诺瓦瓦克斯医药(nvax.us)的新冠疫苗作为加强针。

Valneva COVID-19 vaccine is a COVID-19 vaccine developed by French biotechnology company Valneva SE in collaboration with the American biopharmaceutical company Dynavax Technologies. [7] [8] [9] In April 2022, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) approved the vaccine, being the first in the world to do ...

Valneva’s commercial portfolio is composed of three travel vaccines. IXCHIQ® is approved in the United States, Canada and Europe. Select your country to learn more: For more information about ongoing clinical trials with IXCHIQ® click here. Select your country to learn more: